Phase 2 study met its primary endpoint, demonstrating statistically significant improved overall survival with elraglusib plus ...
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of ...
Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...
SpliceBio has dosed the first patient in the Part B dose-expansion portion of its phase 1/2 ASTRA clinical trial ( ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m2 or greater –– ...
Clinical Trials Arena on MSN
AbCellera begins phase II ABCL635 trial for menopause-related VMS
The Phase II segment is a randomised, double-blind, placebo-controlled study assessing ABCL635 efficacy in 80 postmenopausal ...
Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.
The last time I wrote about Capricor Therapeutics (CAPR) it was with respect to a Seeking Alpha article entitled "Capricor: Maintaining Hold Rating In Light of Deramiocel Complete Response Letter".
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback